Aureka Biotechnologies raises 100 million dollars in Series B funding
Aureka Biotechnologies secured 100 million US dollars in Series B financing to scale biological foundation model training and enhance drug discovery infrastructure
On August 11, 2026, Aureka Biotechnologies announced the successful closure of a US$100 million Series B funding round. The financing, led by Granite Asia, was followed by a substantial investment from a strategic investor, with support from HighLight Capital and participation from existing shareholders, MPCi and NRL Capital. The company has now raised nearly US$200 million to date.
The primary objectives for these funds are to advance the research and development of Aureka's next-generation biological foundation models. These models aim to enhance performance in core tasks such as de novo molecular design, biological structure modeling, and function prediction. Additionally, the company plans to upgrade Lab-in-the-Loop, its experiment-centered feedback engine, which consolidates AI agents, high-throughput digital biology, proprietary single-cell functional screening, and its in-house experimental platform.
This upgraded infrastructure enables Aureka to create a closed-loop system where AI models propose experimentally testable molecular designs and scientific hypotheses. High-quality functional data generated from the experimental platform is then integrated back into the foundation model and project-specific models, fostering continuous iteration and improvement.
This Lab-in-the-Loop mechanism allows Aureka to generate large-scale experimental data crucial for pre-training, reinforcement learning, and project-specific post-training of its foundation models.
The company's advanced infrastructure, exemplified by its AI-native foundation model AuraIDE, has demonstrated superior capabilities in protein structure prediction and de novo molecular design. AuraIDE, trained on proprietary protein co-evolution data, ranks among the leading models in the field. Its versatility allows for the transfer across multiple drug discovery programs through task adaptation and project-specific post-training.
The model's potential to generate biomolecules with intended function through continuous feedback from the closed-loop system positions Aureka Biotechnologies at the forefront of AI-driven drug discovery, pushing the boundaries of both technical innovation and commercial viability in the life sciences industry.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
